Interpretive Handbook

Test
83023 :
Saccharomyces cerevisiae Antibody, IgG, Serum

Inflammatory bowel disease (IBD) refers to 2 diseases, ulcerative colitis (UC) and Crohn's disease (CD), which produce inflammation of the large or small intestines.(1) The diagnoses of both diseases are based on clinical features, radiographic findings, colonoscopy, mucosal biopsy histology, and, in some cases, operative findings and resected bowel pathology and histology.

Patients with IBD have also been shown to have antibodies in serum that help distinguish between CD and UC.(2) Patients with UC often have measurable neutrophil-specific antibodies (NSA) that react with as yet uncharacterized target antigens in human neutrophils; whereas patients with CD often have measurable antibodies of the IgA and/or IgG isotypes that react with cell wall mannan of Saccharomyces cerevisiae strain Su 1.

IBDP / Inflammatory Bowel Disease Serology Panel, Serum is useful as an adjunct in the diagnosis of ulcerative colitis (UC) and Crohn's disease (CD), but should not be relied upon exclusively to establish the diagnosis or to distinguish between these 2 diseases. Some patients with CD have detectable neutrophil-specific antibodies (NSA), and some patients with UC have elevated levels of IgA and/or IgG anti-Saccharomyces cerevisiae antibodies (ASCA).

Measurement of ASCA and NSA are not useful to determine the extent of disease in patients with inflammatory bowel disease or to determine the response to disease-specific therapy including surgical resection of diseased intestine.